Targets › CHEK1
3 programs from 3 companies in 5 trials: 2 Phase 1, 2 Phase 2, 1 Phase 4; Oncology; next expected readout Dec 2026.
Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA. May also negatively regulate cell cycle progression during unperturbed cell cycles. This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome. (UniProt, O14757)
Open in Phaseline: the race on CHEK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospital JP Garrahan | ABVD Combination chemotherapy: Doxorubicin (topoisomerase II inhibitor), Bleomycin (DNA damagin | TOP2A, CHEK1 | Phase 4 | Pediatric Hodgkin's Disease | Oct 2027 |
| Acrivon Therapeutics | Prexasertib (ACR-368) Serine/threonine-protein kinase Chk1 inhibitor; Serine/threonine-protein kinase Chk2 inhibitor | CHEK1, CHEK2 | Phase 2 | Endometrial Adenocarcinoma; Head and Neck Squamous Cell Carcinoma | May 2027 |
| PharmaEngine | PEP07 Selective Chk1 (Checkpoint Kinase 1) inhibitor | CHEK1 | Phase 1 | Acute Myeloid Leukemia; Advanced Solid Tumor | Dec 2026 |
Acute Myeloid Leukemia (1) Advanced Solid Tumor (1) Endometrial Adenocarcinoma (1) Head and Neck Squamous Cell Carcinoma (1) Pediatric Hodgkin's Disease (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.